Objective: Hypothalamic obesity (HO) is an intractable form of obesity syndrome occurring in patients following hypothalamic insults. It is characterized by significant polyphagia, lack of satiety, and rapid weight gain not usually responsive to caloric restriction or lifestyle modification. There are no established treatment modalities for HO. Liraglutide, a glucagon-like peptide-1 analog, has been approved for long-term treatment of obesity. We present a case of successful treatment with liraglutide of HO following resection of craniopharyngioma. Methods: We present a case report and review of the literature. Results: A 23-year-old female had developed panhypopituitarism and HO immediately following resection of a craniopharyngioma at age 8. She complained of poor quality of life due to weight gain from excessive hunger and lack of satiety. A trial of triiodothyronine at age 9, and dextroamphetamine starting at age 13, in addition to lifestyle modification had had limited efficacy. She began treatment w...